Godsey & Gibb Inc’s Vertex Pharmaceuticals VRTX Stock Holding History

Godsey & Gibb Inc’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$523	Buy	+1	New	+$512	﹤0.01%	461

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return

IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

MLL

Moody Lynn & Lieberson Boston, Massachusetts $1.93B AUM 20.85% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return

Godsey & Gibb Inc's VRTX Position: Q3 2026 in Review

Godsey & Gibb Inc opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2026: 1 share worth $523. The stake represents ﹤0.01% of the portfolio and ranks #461 among its holdings.

209 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Godsey & Gibb Inc held 1 share of Vertex Pharmaceuticals worth $523 as of Q3 2026.
Vertex Pharmaceuticals was a new Godsey & Gibb Inc position in Q3 2026.
Vertex Pharmaceuticals made up ﹤0.01% of Godsey & Gibb Inc's portfolio in Q3 2026, its #461 holding.
209 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Godsey & Gibb Inc's 13F filing for Q3 2026, filed 14 Oct 2026.